Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERN study of nivolumab plus radiotherapy in anti-PD-1 pretreated relapsed or refractory classical Hodgkin lymphoma
NL-OMON54697Phase 2Recruiting
- Sponsor
- University of Cologne
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Abscopal response rate at RE-6 (ARR-6). Started Oct 2020; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON54697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54697.